Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial.

Kyung-Hee LeeTae Won KimJung-Hun KangJin-Soo KimJin-Seok AhnSun-Young KimHwan-Jung YunYoung-Jun EumSung Ae KohMin Kyoung KimYong Sang HongJeong Eun KimGyeong-Won Lee
Published in: Chinese journal of cancer (2017)
OXN-CR was non-inferior to OX-CR in terms of pain reduction after 4 weeks of treatment and had a similar safety profile. Studies in larger populations of Korean patients with cancer-related pain are needed to further investigate the effectiveness of OXN-CR for long-term pain control and constipation alleviation. Trial registration ClinicalTrials.gov NCT01313780, registered March 8, 2011.